The implementation of Patents Act, as last amended in 2005, raises significant issues of immediate concern to patients across the world. INDIA'S Patents Act has an interesting history. Enacted first in 1911 as the Indian Patents and Designs Act in the colonial era, it primarily addressed the interests of inventors, who did not want their inventions infringed upon by anyone who copied them or adopted the methods used to make them....

The medicine price regulator, the National Pharmaceutical Pricing Authority (NPPA), has found a price fixing mechanism suggested by its parent ministry, chemicals and fertilisers, has failed to meaningfully lower the prices of key cancer medicines. A group of ministers (GoM) headed by agriculture minister Sharad Pawar is expected to meet soon to finalise a pricing policy on drugs. The NPPA study findings may compel the ministry to seek other effective ways of...

-Economic and Political Weekly The compulsory licence for Nexavar is only the beginning of a new battle over drug prices. The grant of a compulsory licence (CL) to Natco Pharma, a relatively small Indian pharmaceutical company, to manufacture and sell the cancer drug sorafenib (Nexavar) has been rightly hailed as a major step forward for public health and the wider availability of life saving medicines.   The German pharmaceutical company Bayer holds the patent...

Mulling It Over     100% FDI allowed in pharma sector through automatic route     Seven top Indian firms have been acquired by MNCs in the past six years     Fear of price rise in generic medicines if MNCs control market     Health, commerce ministries want FDI to go through approvals     PMO meeting key ministries next month to take a decision *** Prime Minister Manmohan Singh has always been firm in reminding domestic industry that their fear...

The government may approve acquisitions of local drugmakers by global firms on a case-by-case basis on certain conditions to ensure availability of medicines at affordable prices, despite calls for restrictions on such deals in the wake of a spate of takeovers in the last three years. Multinationals may have to move buyout proposals through the Foreign Investment Promotion Board (FIPB), allowing the government to understand the firm's rationale for buying a...